title: Drug resistance factors in acute myeloid leukemia: a comparative analysis.
abstract: To compare the clinical relevance of drug resistance factors in de novo acute myeloid leukemia (AML), we determined their relationship to both response to induction chemotherapy and survival of the patients in univariate as well as multivariate analyses. The drug resistance factors immunocytochemically studied in 111 patients at the time of diagnosis included the lung resistance protein (LRP), P-glycoprotein (P-gp), multidrug resistance protein (MRP1) and bcl-2. In the univariate analyses, age (P = 0.005), karyotype (P = 0.03), LRP (P = 0.003), P-gp (P = 0.02) and bcl-2 (P = 0.03) predicted for response to induction chemotherapy, whereas MRP1 had no predictive value. Age (P = 0.05), karyotype (P = 0.05) and LRP (P = 0.03) retained their predictive value in the multivariate logistic regression analyses. With regard to overall survival, age (P = 0. 008), karyotype (P = 0.006), LRP (P = 0.001) and P-gp (P = 0.01) were of prognostic value in the univariate Cox regression analyses but only age (P = 0.01), karyotype (P = 0.02) and LRP (P = 0.01) retained their prognostic significance in the multivariate analyses. A risk score based on the number of independent prognostic factors allowed division of patients into four groups with different outcome. In these groups, the complete remission rates were 93%, 75%, 47% and 33%, respectively, and median overall survival was 2.4, 1.2, 0.6 and 0.2 years, respectively. Thus, several drug resistance factors did predict outcome in the univariate analyses but LRP was the only drug resistance factor with independent predictive and prognostic significance. The proposed risk score might be useful for risk-adapted treatment in the future. Leukemia (2000) 14, 68-76.
authors.affiliation: Division of Oncology, Department of Internal Medicine I, University of Vienna Medical School, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Filipits
authors.forename: T
authors.initials: T
authors.lastname: Stranzl
authors.forename: G
authors.initials: G
authors.lastname: Pohl
authors.forename: H
authors.initials: H
authors.lastname: Heinzl
authors.forename: U
authors.initials: U
authors.lastname: Jäger
authors.forename: K
authors.initials: K
authors.lastname: Geissler
authors.forename: C
authors.initials: C
authors.lastname: Fonatsch
authors.forename: O A
authors.initials: OA
authors.lastname: Haas
authors.forename: K
authors.initials: K
authors.lastname: Lechner
authors.forename: R
authors.initials: R
authors.lastname: Pirker
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents